Levi & Korsinsky notifies investors that it has commenced an investigation into Theravance Biopharma, Inc. (NASDAQ: TBPH) concerning potential violations of the federal securities laws.
On the Q3 2025 earnings call (November 10, 2025), CEO Rick Winningham stated the Company was "on track to achieve near-term milestones totaling $75 million in the fourth quarter -- $50 million for Trelegy and $25 million for YUPELRI." On the Q2 2025 call (August 12, 2025), CFO Aziz Sawaf reaffirmed "all elements of our 2025 financial guidance." Neither statement addressed the possibility that a CYPRESS failure could trigger an accelerated strategic review, restructuring costs, or a fundamental reassessment of the Company's development-stage spending. On March 3, 2026, Theravance disclosed that the CYPRESS trial failed to meet its primary endpoint and announced an accelerated strategic review, including termination of the ampreloxetine program. The stock fell approximately 26% in a single session.
If you suffered a loss on your Theravance Biopharma, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Tell us the stocks you own using SnapTrade, and we will keep you informed about class action litigation related to your stocks.
We monitor critical case developments that may affect the price of your shares and your possible monetary recovery.
SnapTrade only shares the tickers you own and your transaction history — not your account numbers. Using SnapTrade and participating in our monitoring service is free and does not create an attorney-client relationship or obligation on your part.
Don’t miss out on possible monetary recovery — link your brokerage account with SnapTrade.